Nezam El-Tayebat 事实核查对“نظام الطيبات”饮食体系的科学评估
选择国家
选择语言: 简体中文

错误 已被科学证据否定 证据确定性: 高 初步 C-INS-07

根本不存在1型糖尿病；“1型”是一种主要见于需求量大的运动员的高血糖状态；1型糖尿病患者不会出现并发症；青春期前使用胰岛素是一场灾难（身材矮小、甲状腺问题、囊肿）。

安全提示: 请不要因为这一说法而停用或减少胰岛素。在1型糖尿病和其他胰岛素缺乏的情况下，停用胰岛素会在数小时至数天内导致糖尿病酮症酸中毒，这会危及生命。医学界公认的立场（ADA Standards of Care 2026）：胰岛素治疗对1型糖尿病患者是必不可少的；接受强化胰岛素治疗的人即使不进食，也不应停用基础胰岛素。糖尿病药物的任何调整都应与主治医生共同进行。父母绝不能对患1型糖尿病的孩子停用或不给胰岛素。
简而言之: 该说法错误。1型糖尿病是产生胰岛素的细胞遭到自身免疫破坏所致；在胰岛素问世之前，大多数患1型糖尿病的儿童会在数月至数年内死亡；1型糖尿病患者确实会出现眼、肾、神经和心脏并发症；儿童的生长问题来自控制不佳的糖尿病，而不是来自胰岛素。
结论: 1型糖尿病是存在的，没有胰岛素会致命，而且在任何年龄胰岛素都是必不可少的。
  1. 原始表述
  2. 科学评估
  3. 科学证据详解
  4. 通俗解释
  5. 与该说法相关的研究
  6. 地区背景
  7. 在我的国家适用什么？
  8. 参考文献

原始表述

لان ما فيش حاجه اسمها نوع اول اصلا

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

根本不存在1型糖尿病；“1型”是一种主要见于需求量大的运动员的高血糖状态；1型糖尿病患者不会出现并发症；青春期前使用胰岛素是一场灾难（身材矮小、甲状腺问题、囊肿）。

出处

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
حلقه علميه قويه تواجه التضليل العلمي بالحقيقه (打开来源)
发布日期
2026年4月17日
时间戳
0:30:07 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
所声称的机制

High glucose is an adaptive stress response (athletes, fighters), not insulin deficiency.

所声称的健康影响

Denial of type 1 diabetes as a disease; insulin in children harmful

涉及人群

Children and adults with type 1 diabetes

Elawady 设定的地域限制

none found

来源版本存在差异

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr.D Clinics - Diaa Al Awady is live! (打开来源)
发布日期
2025年1月12日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
السكر جاي منين و الأسيتون رايح فين و الوريد الكبدي المغذي الأوحد في جسم الإنسان (打开来源)
发布日期
2025年9月19日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
ارتفاع السكر والأسيتون ؟خطر والا ده الطبيعي ؟#ضياء_العوضي (打开来源)
发布日期
2025年12月23日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr Diaa Al Awady د ضياء العوضي is live! الموت المفاجيء (打开来源)
发布日期
2025年7月14日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

انت كلامك صح بس احنا برده النوع الاول يا جماعه ينفع معاه النظام بس لازم تكونوا فاهمين حاجه بتاع النوع الاول ده هو مش نوع اول وانسولين صفر مش قصه كده هي القصه ان الاستاذ ابو ابو الصغير الطفل ده اللي بطنه بتتفخ بسرعه قوي >> القذريه عنده [ضحك] بتقع بسرعه قوي فيخش

The system also works for type 1 diabetes; type 1 is 'not a story of zero insulin' but is linked to a child's abdomen bloating very quickly.

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr Diaa Al Awady د ضياء العوضي is live! (打开来源)
发布日期
2025年12月25日
时间戳
0:32:32 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

科学评估

错误 – 该说法与可靠证据相矛盾。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

Type 1 diabetes does not exist; it occurs in athletes; type 1 patients do not suffer complications; insulin before puberty is a catastrophe.

2. 哪些内容可证实是正确的？

Classification of diabetes types has become more detailed (e.g. LADA, MODY, gestational diabetes), which Elawady cites as proof of confusion; this refinement is real but reflects better diagnostics. Poorly controlled diabetes in children can impair growth.

3. 哪些内容是错误或夸大的？

Type 1 diabetes is an autoimmune destruction of insulin-producing cells, leading to absolute insulin deficiency (I-INS-132); without insulin it causes ketoacidosis and death: before insulin most children with diabetes died of coma within months to a few years despite strict diets (I-INS-101), in 2021 about 35,000 undiagnosed people died within 12 months of symptom onset, while a 10-year-old diagnosed in a low-income country can expect about 13 more years of life versus 65 in a high-income country (I-INS-102). 'Lifelong insulin therapy is essential in type 1 diabetes' (ADA/EASD 2026, I-INS-133; ADA 2026, I-ODD-16). Type 1 diabetes is not caused by sport. People with type 1 diabetes do develop retinopathy, nephropathy, neuropathy and heart disease: intensive insulin therapy reduced retinopathy by 76% in the DCCT (I-INS-03), and in Sweden people with T1D had 3.5 times the mortality of controls, 8.5 times with very high HbA1c (I-INS-103). Growth problems in children are caused by poorly controlled diabetes, not by insulin: poor control was associated with 2-3 cm lower adult height (I-INS-105), children on intensive insulin regimens grow normally (I-INS-106), and growth failure from under-treatment (Mauriac syndrome) improves when insulin management is intensified (I-INS-107). Thyroid disease is screened for because autoimmune thyroiditis clusters with type 1 diabetes, not because insulin causes it (I-INS-131).

4. 哪些内容仍不明确？

Nothing material.

5. 哪些研究支持该说法？

None.

6. 哪些研究与该说法相矛盾？

I-INS-03, I-INS-07, I-INS-08, I-ODD-16, I-INS-101, I-INS-102, I-INS-103, I-INS-105, I-INS-106, I-INS-107, I-INS-131, I-INS-132, I-INS-133.

7. 对德国和欧洲而言情况如何？

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. 关于埃及的已知情况是什么？

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. 合理的实际结论是什么？

患1型糖尿病的儿童和成人需要终身使用胰岛素。任何饮食方法都只能在胰岛素治疗之外、在医疗监督下作为补充。

评估详情

证据确定性的依据

Type 1 diabetes as autoimmune beta-cell destruction with absolute insulin deficiency is among the best-established facts of medicine; before insulin was available (1922) it was fatal. Insulin is essential (ADA 2026). DCCT (RCT, 1,441 patients) proved that better insulin treatment reduces complications, which also contradicts 'no complications'.

来源质量

Several machine transcripts, consistent over 2025-2026.

地区可推广性

Universal.

个体例外情况

None. Rare forms (e.g. MODY, some LADA) may initially not need insulin, but this requires specialist diagnosis.

说法的地域范围
普遍性（生物学/医学）
最近审核
2026年10月26日 初步

科学证据详解

已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。

研究问题: Does type 1 diabetes exist as an insulin-deficient disease that is fatal without insulin and causes complications, and does insulin in children cause short stature or thyroid disease?

研究问题详解 (PECO)
人群
Children and adults with type 1 diabetes
干预或暴露
Insulin treatment (vs none/insufficient)
对照
No or inadequate insulin
地域范围
universal biology; Egyptian/Arab-region data on DKA and growth failure
结局指标
  • Survival
  • Complications
  • Growth/adult height
  • Thyroid disease

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

未发现支持该说法的高质量证据。

哪些证据不支持该说法？

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

Type 1 diabetes is autoimmune absolute insulin deficiency, fatal without insulin, causes complications, and insulin protects growth in children.

为什么有些研究权重更大

Natural history, RCTs, nationwide cohorts and all guidelines agree; no supporting evidence was found.

因果关系是否已确立？ 是，已确立 Insulin deficiency causes DKA and death; insulin treatment prevents them; poor control impairs growth.

仍存在的不确定性

None material.

合理的结论

False and dangerous.

这是否取决于国家？
一般生物学效应
Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
饮食习惯
Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
食品原产地
Not relevant.
污染物
Not relevant.
本国生产条件
Not relevant.
法律规则
Insulin is on the WHO Model List of Essential Medicines (not re-verified in this phase).
实际监测数据
Egyptian children often present with severe DKA (I-INS-115); growth failure from under-treatment (Mauriac syndrome) still occurs in the region (Sudan, I-INS-107).

足以改变结论的地区差异没有可靠数据支持。

统计复核
  • Crude risks and CI symmetry – 8.0% vs 2.9% deaths; aHR 3.52 (3.06-4.04) symmetric 已重新计算
  • Crude cumulative mortality by DCCT arm – 6.0% vs 8.8% over about 27 years; HR 0.67 (0.46-0.99) 已重新计算
总体证据的确定性（GRADE，简化版）
主要结局
Survival and complications in type 1 diabetes with vs without adequate insulin
起始等级
低（观察性研究）
升级理由
  • very large effect (natural history: near-universal early death without insulin)
  • dose-response (HbA1c-mortality gradient)
结果
高

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明
  • ADA: 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026 (2026) · 原始文献
    Type 1 diabetes is autoimmune beta-cell destruction usually leading to absolute insulin deficiency; partial remission phase is common after diagnosis.
  • ADA: 14. Children and Adolescents: Standards of Care in Diabetes-2026 (2026) · 原始文献
    For type 1 diabetes 'insulin therapy is paramount'; rec 14.36: start insulin in ketoacidosis; thyroid screening because of autoimmune clustering; in youth T2D maximise non-insulin therapy and consider reducing insulin when goals are met (14.39-14.40).
  • ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
    'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16).
  • ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · 原始文献
    'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant.
  • NICE: NG17 Type 1 diabetes in adults (last updated 17 August 2022) (2022) · 原始文献
    Basal-bolus insulin for all adults with T1D (1.7.1); ketone monitoring in sick-day rules (1.10.1); DKA: isotonic saline and IV insulin infusion (1.10.5-1.10.7).
  • NICE: NG18 Diabetes in children and young people (last updated 11 May 2023) (2023) · 原始文献
    Basal-bolus insulin from diagnosis (1.2.18); blood ketone testing and sick-day rules (1.2.82-1.2.83); DKA is serious and needs urgent hospital IV fluids and insulin (1.4.6, 1.4.21); DKA can occur with normal glucose (1.4.3).
  • WHO: Diabetes fact sheet (14 November 2024) (2024) · 原始文献
    Type 1 diabetes 'requires daily administration of insulin'; chronic hyperglycaemia leads to serious damage to many body systems.
  • ISPAD: ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state (Glaser N et al., PMID 36250645) (2022) · 原始文献 无法获取；内容未采用
检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库日期检索式检索目标命中数纳入数
PubMed2026年10月26日"type 1 diabetes" AND (athletes OR "physical activity" OR exercise) AND (incidence OR risk) AND (cause OR etiology OR onset)支持性证据707
PubMed2026年10月26日(insulin therapy OR insulin treatment) AND children AND ("short stature" OR "growth retardation" OR "growth failure") AND cause支持性证据851
Europe PMC2026年10月26日("type 1 diabetes") AND (TITLE:"without insulin" OR TITLE:"insulin-free" OR TITLE:"off insulin") AND (diet OR "low-carbohydrate" OR survival)支持性证据7
PubMed2026年10月26日"type 1 diabetes" AND (prognosis OR survival OR "life expectancy") AND (pre-insulin OR "before insulin" OR "insulin era" OR "discovery of insulin") 反对性证据4561
PubMed2026年10月26日(insulin access OR insulin availability) AND "type 1 diabetes" AND (mortality OR "life expectancy") AND (Africa OR "low-income")反对性证据19
Europe PMC2026年10月26日(TITLE:"starvation" OR TITLE:"Allen") AND (TITLE:"diabetes") AND (TITLE:"insulin" OR TITLE:"pre-insulin")反对性证据24
Europe PMC2026年10月26日TITLE:"type 1 diabetes" AND (TITLE:"global" AND TITLE:"mortality") AND PUB_YEAR:[2020 TO 2026]反对性证据10
PubMed2026年10月26日Banting[au] AND pancreatic extracts[ti]反对性证据6
PubMed2026年10月26日Lind M[au] AND "Glycemic control and excess mortality in type 1 diabetes"反对性证据6
PubMed2026年10月26日"type 1 diabetes" AND (children OR adolescents) AND (height OR growth OR "final height" OR "adult height") AND (HbA1c OR "metabolic control") AND (cohort OR registry)反对性证据145
PubMed2026年10月26日(Mauriac syndrome) AND (insulin deficiency OR underinsulinization)反对性证据7
Europe PMC2026年10月26日"type 1 diabetes" AND (TITLE:"height" OR TITLE:"growth") AND (TITLE:"children" OR TITLE:"adolescents") AND (TITLE:"glycemic control" OR TITLE:"metabolic control" OR TITLE:"HbA1c" OR TITLE:"glycaemic")反对性证据13
Europe PMC2026年10月26日TITLE:"Standards of Care in Diabetes-2026"指南21
PubMed2026年10月26日ISPAD Clinical Practice Consensus Guidelines 2024指南8
Springer (publisher full text)2026年10月26日Fetched https://link.springer.com/article/10.1007/s00125-026-06833-z (ADA/EASD 2026 T1D consensus)指南1
Guideline websites (NICE)2026年10月26日Fetched https://www.nice.org.uk/guidance/ng17/chapter/Recommendations and /ng18/chapter/Recommendations指南2
WHO website2026年10月26日Fetched https://www.who.int/news-room/fact-sheets/detail/diabetes指南1

核查深度如何？

16 项相关研究：10 项核查了全文（其中 1 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史
  1. 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (高)
  2. 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (高)
    Historical, modelling, registry and growth evidence plus current guidelines unanimously contradict the claim; no supporting evidence was found.
    新来源: I-INS-101 I-INS-102 I-INS-103 I-INS-105 I-INS-106 I-INS-107 I-INS-131 I-INS-132 I-INS-133 I-INS-134 I-INS-135 I-INS-137

通俗解释

1型糖尿病是一种真实存在的疾病，在这种疾病中，身体的免疫系统会破坏产生胰岛素的细胞。如果不注射胰岛素，1型糖尿病患者（包括儿童）会在几天内病情严重，并可能死亡。胰岛素治疗能保护他们的眼睛、肾脏和神经。说1型糖尿病不存在，是错误且危险的。

与该说法相关的研究

支持该说法的研究 (0)

该组中没有研究。

与该说法相矛盾或限制该说法的研究 (16)

  • DCCT: better insulin treatment in type 1 diabetes

    Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Does intensive insulin therapy reduce long-term complications in type 1 diabetes?

    研究是如何开展的？

    Multicentre RCT (DCCT)

    研究了多少人、动物或样本？

    1,441; Insulin-dependent (type 1) diabetes

    实际发现了什么？

    Large reductions in all microvascular complications.

    观察到的效应有多大？

    Retinopathy -76%

    研究结果对日常生活意味着什么？

    Insulin protects eyes, kidneys and nerves in type 1 diabetes.

    该研究有哪些局限？

    Open-label; Selected young population

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).

    研究结果是否适用于德国和欧洲？

    North American; universally accepted.

    从该研究中明确不能得出什么结论？

    Effects in type 2 diabetes directly.

    科学细节 →

  • International guideline on diabetic ketoacidosis

    Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Insulin, fluids and potassium are the core treatment; with this, fewer than 1% of adults die.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Diagnosis and management of DKA and HHS in adults

    研究是如何开展的？

    International consensus report based on systematic examination of literature since 2009 (ADA, EASD, JBDS, AACE, DTS)

    研究了多少人、动物或样本？

    not applicable; Adults with diabetes

    实际发现了什么？

    Insulin is the cornerstone; glucocorticoids worsen hyperglycaemia.

    观察到的效应有多大？

    Mortality <1% with treatment

    研究结果对日常生活意味着什么？

    Ketoacidosis needs hospital treatment with insulin.

    该研究有哪些局限？

    Consensus, not trial

    它对 Elawady 的具体说法说明了什么？

    Directly contradicts C-INS-08; supports danger in C-FAST-03; contradicts C-INS-07, C-INS-10.

    研究结果是否适用于德国和欧洲？

    EASD and JBDS (UK) co-authored; directly applicable.

    从该研究中明确不能得出什么结论？

    Outcomes of untreated DKA quantitatively.

    科学细节 →

  • Review on diabetic ketoacidosis

    Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
    叙述性综述独立交叉核查全文，含结构化偏倚风险评估

    DKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Epidemiology, pathogenesis, diagnosis and management of DKA

    研究是如何开展的？

    Narrative expert review (Nature Reviews Disease Primers)

    研究了多少人、动物或样本？

    not applicable; Adults and children with diabetes

    实际发现了什么？

    DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.

    观察到的效应有多大？

    not applicable

    研究结果对日常生活意味着什么？

    DKA is an emergency.

    该研究有哪些局限？

    Narrative expert review without systematic methods; one author has research support from insulin makers.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-08, C-INS-02, C-FAST-01, C-FAST-03.

    研究结果是否适用于德国和欧洲？

    International.

    从该研究中明确不能得出什么结论？

    Quantitative estimates.

    科学细节 →

  • ADA guideline 2026: diabetes medicines

    American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Pharmacologic glycaemic treatment

    研究是如何开展的？

    Clinical practice guideline (ADA Standards of Care 2026, Section 9)

    研究了多少人、动物或样本？

    not applicable; People with type 1 and type 2 diabetes

    实际发现了什么？

    See results.

    观察到的效应有多大？

    not applicable

    研究结果对日常生活意味着什么？

    Medicines chosen by benefit-risk.

    该研究有哪些局限？

    Partially read

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07, C-INS-10, C-ODD-06; supports C-ODD-07, C-INS-11.

    研究结果是否适用于德国和欧洲？

    Consistent with ADA/EASD consensus.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • What happened to people with diabetes before insulin existed

    Mazur A. Nutr J 2011 · PMID 21396115 · DOI 10.1186/1475-2891-10-23
    叙述性综述独立交叉核查已核查全文★ 关键研究

    Before 1922, children with diabetes usually died of diabetic coma within months to a few years, even on strict fasting diets; some starved to death.

    Before insulin, type 1-like diabetes in children was fatal within months to years despite diet.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    To explain why fasting diets were used for diabetes before insulin and how patients fared.

    研究是如何开展的？

    Historical analysis of published case series and textbooks.

    研究了多少人、动物或样本？

    Patients of Allen (76 published cases) and Joslin, 1914-1922.

    实际发现了什么？

    Most children died of coma within months to years; 43% of Allen's cases were dead by 1917; four died of starvation; diabetes was not cured.

    观察到的效应有多大？

    43% mortality within a few years (Allen's series).

    研究结果对日常生活意味着什么？

    Diet and fasting alone cannot keep insulin-deficient diabetes alive; insulin changed this.

    该研究有哪些局限？

    Historical, uncontrolled data; diabetes types not distinguished.

    它对 Elawady 的具体说法说明了什么？

    Contradicts claims that diet can replace insulin or that ketoacidosis does not kill.

    研究结果是否适用于德国和欧洲？

    Universal biology.

    从该研究中明确不能得出什么结论？

    Cannot give exact survival curves or separate type 1 from type 2 cases.

    科学细节 →

  • How many people have type 1 diabetes worldwide and how long they live

    Gregory GA et al.. Lancet Diabetes Endocrinol 2022 · PMID 36113507 · DOI 10.1016/S2213-8587(22)00218-2
    其他独立交叉核查已核查摘要★ 关键研究

    About 8.4 million people had type 1 diabetes in 2021; a 10-year-old diagnosed in a low-income country could expect about 13 more years of life, versus 65 in a high-income country.

    T1D exists in 8.4 million people; without diagnosis/treatment death within a year; life expectancy 13 vs 65 years by country income.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Estimate the global burden of type 1 diabetes.

    研究是如何开展的？

    Computer model fitted to registry and published data from many countries.

    研究了多少人、动物或样本？

    Model of 201 countries.

    实际发现了什么？

    8.4 million cases; 35,000 undiagnosed deaths within a year of symptoms; life expectancy gap 13 vs 65 years.

    观察到的效应有多大？

    Life expectancy difference about 52 years for a child diagnosed at 10.

    研究结果对日常生活意味着什么？

    Where insulin and care are hard to get, children with type 1 diabetes die young.

    该研究有哪些局限？

    Model estimates with uncertainty; funded by a T1D charity.

    它对 Elawady 的具体说法说明了什么？

    Contradicts 'type 1 does not exist' and any advice to stop insulin.

    研究结果是否适用于德国和欧洲？

    Europe is in the high-income group with long survival under insulin treatment.

    从该研究中明确不能得出什么结论？

    Cannot attribute individual deaths to specific causes.

    科学细节 →

  • Blood sugar control and death in type 1 diabetes in Sweden

    Lind M et al.. N Engl J Med 2014 · PMID 25409370 · DOI 10.1056/NEJMoa1408214
    队列研究独立交叉核查已核查摘要★ 关键研究

    People with type 1 diabetes died about 3.5 times as often as matched controls; with very high HbA1c the risk was about 8.5 times higher.

    Excess CV death in T1D (HR 4.60) contradicts 'no complications'.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Measure excess mortality in T1D by glucose control.

    研究是如何开展的？

    Nationwide register with matched controls.

    研究了多少人、动物或样本？

    33,915 patients, 169,249 controls.

    实际发现了什么？

    Higher HbA1c, higher death risk; excess risk even with good control.

    观察到的效应有多大？

    HR 3.52 overall; 8.51 at HbA1c >=9.7%.

    研究结果对日常生活意味着什么？

    Type 1 diabetes shortens life, especially with high sugar.

    该研究有哪些局限？

    Observational data.

    它对 Elawady 的具体说法说明了什么？

    Contradicts denial of T1D complications and 'high sugar protects'.

    研究结果是否适用于德国和欧洲？

    Swedish data, directly applicable to Europe.

    从该研究中明确不能得出什么结论？

    Cannot prove that lowering HbA1c alone removes all excess risk.

    科学细节 →

  • Blood sugar control in childhood type 1 diabetes and adult height

    Smew AI et al.. J Clin Endocrinol Metab 2025 · PMID 39556501 · DOI 10.1210/clinem/dgae809
    队列研究独立交叉核查已核查摘要★ 关键研究

    Children with poorly controlled type 1 diabetes ended up about 2-3 cm shorter as adults than those with good control.

    Short stature associated with poor control, not with insulin treatment.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Relate childhood glucose control to adult height.

    研究是如何开展的？

    Nationwide register study.

    研究了多少人、动物或样本？

    Swedish children with T1D.

    实际发现了什么？

    Poor control = lower adult height.

    观察到的效应有多大？

    -2.9 cm (males), -1.8 cm (females).

    研究结果对日常生活意味着什么？

    Keeping blood sugar well controlled with insulin protects growth.

    该研究有哪些局限？

    Observational.

    它对 Elawady 的具体说法说明了什么？

    Contradicts the idea that insulin itself causes short stature.

    研究结果是否适用于德国和欧洲？

    Swedish data; applicable to Europe.

    从该研究中明确不能得出什么结论？

    Cannot exclude other factors linked to poor control.

    科学细节 →

  • Height of children with type 1 diabetes and their insulin treatment

    Svensson J et al.. Pediatr Diabetes 2018 · PMID 30105887 · DOI 10.1111/pedi.12751
    横断面研究独立交叉核查已核查摘要★ 关键研究

    In about 23,000 young people, those on more intensive insulin treatment were taller; major growth problems were virtually absent with modern care.

    Intensive insulin (pumps) associated with taller stature; growth disturbances virtually eliminated with modern care.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Describe height by treatment and control in youth with T1D.

    研究是如何开展的？

    International registry, cross-sectional.

    研究了多少人、动物或样本？

    22,941 young people.

    实际发现了什么？

    Height normal or above; pumps and good control linked to taller height.

    观察到的效应有多大？

    z-score 0.35 vs 0.19.

    研究结果对日常生活意味着什么？

    Modern insulin treatment lets children grow normally.

    该研究有哪些局限？

    Cross-sectional; industry funding.

    它对 Elawady 的具体说法说明了什么？

    Contradicts 'insulin before puberty is a catastrophe'.

    研究结果是否适用于德国和欧洲？

    Includes European centres.

    从该研究中明确不能得出什么结论？

    Cannot prove causality.

    科学细节 →

  • Growth failure from poorly controlled type 1 diabetes in Sudan

    Ismail MM et al.. Pediatr Diabetes 2025 · PMID 40904852 · DOI 10.1155/pedi/7047312
    病例系列 / 病例报告独立交叉核查已核查摘要★ 关键研究

    Children with long-standing poor control were short and had enlarged livers; most improved when their insulin treatment was intensified.

    Short stature arises from poor control and improved with intensified insulin management.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Describe Mauriac syndrome in Sudanese children.

    研究是如何开展的？

    Record review with follow-up.

    研究了多少人、动物或样本？

    37 children.

    实际发现了什么？

    57% improved with better control; nephropathy in one third.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Too little insulin effect, not insulin itself, stunts growth.

    该研究有哪些局限？

    Small, no control group.

    它对 Elawady 的具体说法说明了什么？

    Contradicts 'insulin causes short stature'.

    研究结果是否适用于德国和欧洲？

    Rare in Europe today.

    从该研究中明确不能得出什么结论？

    Cannot give exact effect sizes.

    科学细节 →

  • US diabetes standards 2026: children and adolescents

    American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Insulin is essential for children with type 1 diabetes; in youth with type 2 diabetes, insulin can be reduced when goals are met.

    Insulin therapy paramount for children with T1D; thyroid screening because of autoimmune clustering.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Guide paediatric diabetes care.

    研究是如何开展的？

    Evidence-graded guideline.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Insulin paramount in T1D; insulin for ketoacidosis.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Children with type 1 diabetes need insulin.

    该研究有哪些局限？

    Guideline.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07; supports C-INS-11.

    研究结果是否适用于德国和欧洲？

    European paediatric guidance (ISPAD, NICE NG18) agrees.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • US diabetes standards 2026: what type 1 diabetes is

    American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358893 · DOI 10.2337/dc26-S002
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Type 1 diabetes is an autoimmune destruction of insulin-producing cells that leads to absolute insulin deficiency.

    T1D = autoimmune beta-cell destruction with absolute insulin deficiency.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Define diabetes types.

    研究是如何开展的？

    Guideline.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    T1D = autoimmune, insulin-deficient; 5-10% of diabetes.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Type 1 diabetes is real and needs insulin.

    该研究有哪些局限？

    Guideline.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07.

    研究结果是否适用于德国和欧洲？

    Identical European definitions.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • European and US consensus 2026 on type 1 diabetes in adults

    Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Lifelong insulin is essential in type 1 diabetes, and everyone with type 1 diabetes should be able to test glucose and ketones.

    Lifelong insulin essential in T1D.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Update guidance on adult T1D care.

    研究是如何开展的？

    Consensus report.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Insulin lifelong and essential; ketone testing for all.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    People with type 1 diabetes must never stop insulin.

    该研究有哪些局限？

    Consensus.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07/09/10; supports C-INS-11.

    研究结果是否适用于德国和欧洲？

    European (EASD) guidance.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management

    National Institute for Health and Care Excellence (NICE). NICE guideline 2015
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    UK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.

    Basal-bolus insulin for all adults with T1D.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    National guidance.

    研究是如何开展的？

    Evidence-based guideline.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Rec 1.7.1: offer multiple daily injection basal-bolus insulin regimens as the regimen of choice for all adults with T1D. Rec 1.10.1: consider ketone monitoring as part of sick-day rules. Recs 1.10.5-1.10.7: use isotonic saline for fluid replacement in DKA and give intravenous insulin by infusion. Misdiagnosis of T1D as T2D 'could lead to the person not receiving insulin treatment and a subsequent risk of diabetic ketoacidosis'.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    UK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.

    该研究有哪些局限？

    Guideline.

    它对 Elawady 的具体说法说明了什么？

    Contradicts insulin-free management.

    研究结果是否适用于德国和欧洲？

    UK.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • NICE guideline NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management

    National Institute for Health and Care Excellence (NICE). NICE guideline 2015
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    UK paediatric guideline: insulin from diagnosis; DKA needs urgent hospital IV fluids and insulin; honeymoon phase is temporary.

    Children with T1D: basal-bolus insulin from diagnosis.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    National guidance.

    研究是如何开展的？

    Evidence-based guideline.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Rec 1.2.18: offer children and young people with T1D a multiple daily injection basal-bolus insulin regimen from diagnosis. Recs 1.2.82-1.2.83: sick-day rules including blood ketone monitoring; offer blood ketone strips and meter. Rec 1.4.3: children taking insulin may develop DKA with normal blood glucose. Rec 1.4.6: explain that DKA is serious and needs urgent hospital assessment. Rec 1.4.21: treat DKA with intravenous fluids and intravenous insulin if the child is not alert, nauseated/vomiting or clinically dehydrated. Rec 1.2.25: explain the partial remission ('honeymoon') phase with low insulin needs.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    UK paediatric guideline: insulin from diagnosis; DKA needs urgent hospital IV fluids and insulin; honeymoon phase is temporary.

    该研究有哪些局限？

    Guideline.

    它对 Elawady 的具体说法说明了什么？

    Contradicts insulin-free management.

    研究结果是否适用于德国和欧洲？

    UK.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • WHO: key facts on diabetes

    World Health Organization. WHO fact sheet 2024
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Type 1 diabetes requires daily insulin; long-term high blood sugar damages nerves, blood vessels and organs.

    T1D requires daily insulin.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Inform the public.

    研究是如何开展的？

    Fact sheet.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    T1D needs daily insulin.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Type 1 diabetes needs insulin every day.

    该研究有哪些局限？

    Not graded.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07 and C-DIAB-01.

    研究结果是否适用于德国和欧洲？

    Global.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

结果不一或不明确的研究 (0)

该组中没有研究。

地区背景

德国 / 欧盟

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

埃及

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

在我的国家适用什么？

一般科学评估

错误 1型糖尿病是存在的，没有胰岛素会致命，而且在任何年龄胰岛素都是必不可少的。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

  1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
  2. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.. Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032
  3. Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
  4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
  5. Why were "starvation diets" promoted for diabetes in the pre-insulin period?. Mazur A. Nutr J 2011 · PMID 21396115 · DOI 10.1186/1475-2891-10-23
  6. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.. Gregory GA et al.. Lancet Diabetes Endocrinol 2022 · PMID 36113507 · DOI 10.1016/S2213-8587(22)00218-2
  7. Glycemic control and excess mortality in type 1 diabetes.. Lind M et al.. N Engl J Med 2014 · PMID 25409370 · DOI 10.1056/NEJMoa1408214
  8. Glycemic Control and Adult Height: A Nationwide Swedish Cohort Study on Childhood Type 1 Diabetes.. Smew AI et al.. J Clin Endocrinol Metab 2025 · PMID 39556501 · DOI 10.1210/clinem/dgae809
  9. The influence of treatment, age at onset, and metabolic control on height in children and adolescents with type 1 diabetes-A SWEET collaborative study.. Svensson J et al.. Pediatr Diabetes 2018 · PMID 30105887 · DOI 10.1111/pedi.12751
  10. Mauriac Syndrome in Sudanese Children: An Old Syndrome Still Existing in Resource-Limited Countries.. Ismail MM et al.. Pediatr Diabetes 2025 · PMID 40904852 · DOI 10.1155/pedi/7047312
  11. 14. Children and Adolescents: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014
  12. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358893 · DOI 10.2337/dc26-S002
  13. The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
  14. NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015
  15. NICE guideline NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015
  16. Diabetes (fact sheet). World Health Organization. WHO fact sheet 2024

← 返回概览